Bavarian Nordic A/S/€BAVA

1D1W1MYTD1Y5YMAX

About Bavarian Nordic A/S

Bavarian Nordic A/S is a biotechnology company based in Denmark, primarily focused on the development, manufacture, and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company's product portfolio includes vaccines for smallpox, Ebola, and other infectious diseases, with its most notable products being the smallpox and monkeypox vaccine, Jynneos (also known as Imvanex or Imvamune). Founded in 1994, Bavarian Nordic has established partnerships with several government agencies, enhancing its strategic positioning in the vaccine development sector. The company operates globally, with its headquarters located in Kvistgaard, Denmark, and manufacturing facilities in various locations supporting its international distribution efforts. Bavarian Nordic leverages proprietary vaccine platform technologies such as MVA-BN, contributing to its competitive advantage in the biotechnology industry.
Ticker
€BAVA
Sector
Health
Primary listing
XGAT
Employees
1,906
Headquarters
Hellerup, Denmark
Website
www.bavarian-nordic.com

BAVA Metrics

BasicAdvanced
€2.1B
10.72
€2.60
0.94
-

Bulls say / Bears say

Bavarian Nordic reported strong first-half execution, with Q2 revenue up 23% year over year, Travel Health revenue up 45%, and upgraded 2026 guidance to approximately DKK 5.7 billion of revenue and a 30% EBITDA margin. (Bavarian Nordic)
Government demand is providing improved forward visibility: Bavarian Nordic secured an additional smallpox/mpox contract worth more than DKK 700 million, with most revenue expected in 2027, bringing secured 2026 Public Preparedness contracts to approximately DKK 2.2 billion. (Bavarian Nordic)
The European Commission expanded MVA-BN’s authorization to children aged 2 to under 12, enlarging the addressable population for Bavarian Nordic’s mpox/smallpox vaccine and strengthening its public-health preparedness franchise. (Bavarian Nordic)
Public-preparedness revenue remains lumpy: Q1 2026 total revenue fell 21% year over year, while JYNNEOS/IMVANEX/IMVAMUNE revenue dropped 53% and management said 2026 is not expected to benefit materially from mpox outbreaks. (Bavarian Nordic)
CEO Paul Chaplin is due to leave after leading Bavarian Nordic since 2014, creating leadership-transition risk during the company’s strategic shift toward travel-health growth and less outbreak-driven revenue. (Bloomberg)
The chikungunya growth thesis still depends on regulatory and commercial execution: the Brazilian marketing application was only submitted in July 2026, so approval, launch timing and meaningful revenue contribution remain uncertain. (Bavarian Nordic)
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2026.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.